<DOC>
	<DOCNO>NCT01979939</DOCNO>
	<brief_summary>To demonstrate effectiveness DCV 3DAA fix dose regimen treatment naive treatment experience non-cirrhotic subject</brief_summary>
	<brief_title>UNITY 1 : A Study Investigational Treatment Regimen Daclatasvir ( DCV ) + Asunaprevir ( ASV ) + BMS-791325 Fixed Dose Combination ( DCV 3DAA ( Direct Acting Antiviral ) Regimen ) 12 Weeks Treatment Chronic Hepatitis C Virus ( HCV ) Genotype 1 Infection Non-cirrhotic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects chronically infect HCV genotype 1 HCV RNA ≥ 10,000 IU/mL screen Treatmentnaïve subject previous exposure interferon formulation ( ie , IFNα , pegIFNα ) , RBV , HCV DAA ( protease , polymerase inhibitor , etc . ) Treatmentexperienced subject eligible Evidence cirrhosis Liver organ transplant Current known history cancer within 5 year prior enrollment Documented suspect HCC Evidence decompensated liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>